The SAVOR-TIMI 53 CVOT assessed the cardiovascular effect of saxagliptin in patients with type 2 diabetes with high CV risk, or prior CV events. This module details the results.
SAVOR-TIMI 53
SAVOR-TIMI 53: trial design
SAVOR-TIMI 53: baseline characteristics
SAVOR-TIMI 53: CV disease at baseline
SAVOR-TIMI 53: kidney function at baseline
SAVOR-TIMI 53: glucose-lowering medication and CV medication at baseline
SAVOR-TIMI 53: 3P-MACE primary outcome
SAVOR-TIMI 53: components of 3P-MACE and all-cause mortality